Veradermics, Incorporated (MANE)

Insider Selling: Veradermics (NYSE:MANE) Director Sells $10,712,000.00 in Stock

Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Veradermics: VDPHL01 Looks Promising Enough On Paper

Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302' in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy

Veradermics (NYSE:MANE) Shares Gap Up After Analyst Upgrade

Veradermics' Oral Hair Loss Drug for Women Shows Results In Just 2 Months

Veradermics, Incorporated (MANE) Discusses Positive Female Results From Phase II Study of VDPHL01 for Pattern Hair Loss Transcript

Veradermics Hair Loss Pill Shows Strong Phase II Signal in Women

Veradermics' Oral VDPHL01 Delivers Positive Study ‘207' Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study ‘306' Readout

Veradermics to Hold Conference Call to Discuss Study ‘207' Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair Loss

Biotech ETF Index Surges 10% After Rebalance

Can Veradermics (MANE) Climb 27.65% to Reach the Level Wall Street Analysts Expect?

Veradermics, Incorporated (MANE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript

Veradermics to Present at Upcoming June Investor Conferences

Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 '302' Study of VDPHL01 at the 2026 World Congress for Hair Research

Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 ‘302' Study of VDPHL01 at the 2026 World Congress for Hair Research